The Investor
28 Feb 2026, 15:13
Edwards Lifesciences Corporation highlighted its continued focus on structural heart innovation and expanded access to care, reaffirming its global health initiative, Every Heartbeat Matters.
As part of the update, the company announced a renewed goal to help 2 million additional patients facing access barriers receive lifesaving structural heart treatment by the end of 2030. Since its launch in 2014, Every Heartbeat Matters and its charitable partners have impacted more than 4 million underserved structural heart patients globally, particularly in low- and middle-income countries.
Management emphasized that the initiative, supported by the Edwards Lifesciences Foundation, aims to reduce financial, systemic and geographic barriers to diagnosis and treatment. The company stated that innovation, clinical expertise and global healthcare partnerships remain central to its strategy to advance science and expand patient access.
Source: Edwards Lifesciences, Business Wire, February 26, 2026.
As part of the update, the company announced a renewed goal to help 2 million additional patients facing access barriers receive lifesaving structural heart treatment by the end of 2030. Since its launch in 2014, Every Heartbeat Matters and its charitable partners have impacted more than 4 million underserved structural heart patients globally, particularly in low- and middle-income countries.
Management emphasized that the initiative, supported by the Edwards Lifesciences Foundation, aims to reduce financial, systemic and geographic barriers to diagnosis and treatment. The company stated that innovation, clinical expertise and global healthcare partnerships remain central to its strategy to advance science and expand patient access.
Source: Edwards Lifesciences, Business Wire, February 26, 2026.
